Objective To observe the expression of E‐cadherin in meningioma ,and discuss its the relationship with and meningioma pathology grading ,further explore the effect of E cadherin in invasive behavior and recurrence ,and analyze the clinical significance of E‐cadherin in the diagnosis and treatment of meningioma.Methods 48 cases of patients with meningioma from January 2005 to January 2014 in our hospital were selected as research objects. Immunohistochemical method was used to test the expression of E‐cadherin for patients with meningioma. Expressions under the conditions of invasive behavior and re‐currence in different pathological grading ,and edema were studied. The relationship between E‐cadherin and meningioma path‐ological grading were explored. Results Based on the expression result of E‐cadherin under different pathological grading ,the negative expression rate of grade Ⅰ was 10.3% ,grade Ⅱ was 60.0% ,and grade Ⅲ was 100%. The difference was significant (P<0.05);Based on the expression result of E‐cadherin under different edema grading ,the negative expression rate of grade 1 was 15.8% ,grade 2 was 62.5% ,and grade 3 was 100.0%. The difference was significant(P<0.05);the specimens were di‐vided in invasiveness group and no invasion group based on the invasion condition. The negative expression rate of the invasive‐ness group was 53.8% ,and no invasion group was 14.3%. The difference was statistically significant(P<0.05). The speci‐mens were divided into recurrence group and no recurrence group based on recurrence condition. The negative expression rate of the recurrence group was 66.7% ,and rate of no recurrence group was 15.4%. The difference was significant(P<0.05). Con‐clusion E‐cadherin expression is closely related with meningioma pathological grading ,edema ,recurrence rate ,and invasion. Testing the expression of E‐cadherin in the meningioma helps to explore the biological behavior of meningioma ,which is signifi‐cant for disease progression and prognosis.%目的：观察E‐钙黏附素在脑膜瘤中的表达情况，同时对其表达与脑膜瘤病理分级的关系进行探讨，进一步探讨E‐钙黏附素在脑膜瘤侵袭行为、复发等方面的作用，分析E‐钙黏附素在脑膜瘤诊断和治疗中的临床意义。方法入选2005‐01—2014‐01于我院就诊的脑膜瘤患者48例作为研究对象，应用免疫组织化学法对患者脑膜瘤组织中 E‐钙黏附素表达进行检测，针对不同病理分级、水肿情况、是否存在侵袭行为和是否复发等情况下的表达进行分析，分析E‐钙黏附素与脑膜瘤病理学分级的关系。结果根据病理学分级探查不同病理分级 E‐钙黏附素表达情况显示，Ⅰ级阴性表达率10.3％，Ⅱ级为60.0％，Ⅲ级为100.0％，差异有统计学意义（ P＜0.05）；根据瘤周水肿分级探查不同级别水肿E‐钙黏附素表达情况显示，0级阴性表达率6.7％，1级为15.8％，2级为62.5％，3级为100.0％，差异有统计学意义（P＜0.05）；根据有无侵袭力将纳入标本分为有侵袭力组和无侵袭力组，有侵袭力阴性表达率为53.8％，无侵袭力为14.3％，差异有统计学意义（P＜0.05）；根据复发情况将入选标本分为又复发组和无复发组，复发组阴性表达率为66.7％，无复发组为15.4％，差异有统计学意义（P＜0.05）。结论 E‐钙黏附素与脑膜瘤病理分级、瘤周水肿、复发和侵袭力有密切关系，检测E‐钙黏附素在脑膜瘤组织中的表达有利于探查脑膜瘤生物学行为，对判断疾病发展和预后有重要的意义。
展开▼
